ES2192949B1 - Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop. - Google Patents

Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop.

Info

Publication number
ES2192949B1
ES2192949B1 ES200101824A ES200101824A ES2192949B1 ES 2192949 B1 ES2192949 B1 ES 2192949B1 ES 200101824 A ES200101824 A ES 200101824A ES 200101824 A ES200101824 A ES 200101824A ES 2192949 B1 ES2192949 B1 ES 2192949B1
Authority
ES
Spain
Prior art keywords
phop
virulence
mutant
mycobacterium tuberculosis
gen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200101824A
Other languages
English (en)
Other versions
ES2192949A1 (es
Inventor
Carlos Martin Montañes
Brigitte Gicquel
Esther Perez Herran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Zaragoza
Original Assignee
Universidad de Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200101824A priority Critical patent/ES2192949B1/es
Application filed by Universidad de Zaragoza filed Critical Universidad de Zaragoza
Priority to PCT/ES2002/000381 priority patent/WO2003012075A1/es
Priority to ES02751195T priority patent/ES2316590T3/es
Priority to PT02751195T priority patent/PT1428870E/pt
Priority to CA2456007A priority patent/CA2456007C/en
Priority to US10/485,372 priority patent/US7468190B2/en
Priority to EP02751195A priority patent/EP1428870B1/en
Priority to AT02751195T priority patent/ATE414761T1/de
Priority to DE60229962T priority patent/DE60229962D1/de
Priority to JP2003517253A priority patent/JP4153423B2/ja
Publication of ES2192949A1 publication Critical patent/ES2192949A1/es
Application granted granted Critical
Publication of ES2192949B1 publication Critical patent/ES2192949B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La construcción de un mutante por recombinación homóloga a partir de un aislado clínico de Mycobacterium tuberculosis en el que se inactiva el gen phoP, atenúa su virulencia en el macrófago de médula ósea de ratón. El mutante phoP también disminuye su virulencia en el modelo experimental de ratón. Este mutante phoP es además capaz de persistir sin ser eliminado tanto en el macrófago como en el ratón.
ES200101824A 2001-07-31 2001-07-31 Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop. Expired - Fee Related ES2192949B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES200101824A ES2192949B1 (es) 2001-07-31 2001-07-31 Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop.
DE60229962T DE60229962D1 (de) 2001-07-31 2002-07-30 Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
PT02751195T PT1428870E (pt) 2001-07-31 2002-07-30 Redução da virulência de mycobacterium tuberculosis e protecção contra a tuberculose pela inactivação do gene phop
CA2456007A CA2456007C (en) 2001-07-31 2002-07-30 Reduction in the virulence of mycobacterium tuberculosis and protection against tuberculosis by means of phop gene inactivation
US10/485,372 US7468190B2 (en) 2001-07-31 2002-07-30 Reduction in the virulence of Mycobacterium tuberculosis and protection against tuberculosis by means of phoP gene inactivation
EP02751195A EP1428870B1 (en) 2001-07-31 2002-07-30 Reduction in the virulence of mycobacterium tuberculosis and protection against tuberculosis by means of phop gene inactivation
PCT/ES2002/000381 WO2003012075A1 (es) 2001-07-31 2002-07-30 DISMINUCIÓN DE VIRULENCIA DE MYCOBACTERIUM TUBERCULOSIS Y PROTECCIÓN CONTRA LA TUBERCULOSIS POR LA INACTIVACIÓN DEL GEN phoP
ES02751195T ES2316590T3 (es) 2001-07-31 2002-07-30 Reduccion de la virulencia de mycobacterium tuberculosis y proteccion frente a la tuberculosis mediante la inactivacion del gen phop.
JP2003517253A JP4153423B2 (ja) 2001-07-31 2002-07-30 ミコバクテリウム結核菌の毒力の減少およびｐｈｏＰ遺伝子の不活性化による結核菌に対する保護
AT02751195T ATE414761T1 (de) 2001-07-31 2002-07-30 Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200101824A ES2192949B1 (es) 2001-07-31 2001-07-31 Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop.

Publications (2)

Publication Number Publication Date
ES2192949A1 ES2192949A1 (es) 2003-10-16
ES2192949B1 true ES2192949B1 (es) 2004-08-16

Family

ID=8498623

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200101824A Expired - Fee Related ES2192949B1 (es) 2001-07-31 2001-07-31 Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop.
ES02751195T Expired - Lifetime ES2316590T3 (es) 2001-07-31 2002-07-30 Reduccion de la virulencia de mycobacterium tuberculosis y proteccion frente a la tuberculosis mediante la inactivacion del gen phop.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02751195T Expired - Lifetime ES2316590T3 (es) 2001-07-31 2002-07-30 Reduccion de la virulencia de mycobacterium tuberculosis y proteccion frente a la tuberculosis mediante la inactivacion del gen phop.

Country Status (9)

Country Link
US (1) US7468190B2 (es)
EP (1) EP1428870B1 (es)
JP (1) JP4153423B2 (es)
AT (1) ATE414761T1 (es)
CA (1) CA2456007C (es)
DE (1) DE60229962D1 (es)
ES (2) ES2192949B1 (es)
PT (1) PT1428870E (es)
WO (1) WO2003012075A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2433518T3 (es) * 2006-03-24 2013-12-11 Universidad De Zaragoza Vacuna contra la tuberculosis
WO2009025888A2 (en) * 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
WO2008141226A2 (en) * 2007-05-10 2008-11-20 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2009046449A1 (en) * 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) * 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
CN102439134B (zh) * 2010-04-22 2016-01-20 刘军 包含过表达PhoP和/或PhoP调节子蛋白的重组BCG菌株的结核疫苗
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
CN109423479A (zh) * 2017-09-05 2019-03-05 江苏齐氏生物科技有限公司 一种大鼠骨髓巨噬细胞分离及培养方法
CN109810932A (zh) * 2019-02-09 2019-05-28 济宁医学院 新疆地区的结核分枝杆菌临床分离株中存在PhoP基因的天然缺失突变菌株

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645489B2 (en) * 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
US5843426A (en) 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PÉREZ, E. et al. "An essential role for pho P in Mycobacterium tuberculosis virulence". MOLECULAR MICROBIOLOGY, 2001, Vol. 41, Nº 1, páginas 179-187. Todo el documento. *
ZAHRT, T.C. et al. "An essential two-component signal transduction system in Mycobacterium tuberculosis". JOURNAL OF BACTERIOLOGY, 2000, Vol. 182, Nº 13, páginas 3832-3838. Todo el documento. *
ZAHRT, T.C. et al. "Elements of signal transduction in Mycobacterium tuberculosis: In vitro phosphorylation an in vivo expression of the response regulator MtrA". JOURNAL OF BACTERIOLOGY, 1996, Vol. 178. *

Also Published As

Publication number Publication date
ES2192949A1 (es) 2003-10-16
DE60229962D1 (de) 2009-01-02
US20050106175A1 (en) 2005-05-19
JP4153423B2 (ja) 2008-09-24
EP1428870A1 (en) 2004-06-16
JP2004535827A (ja) 2004-12-02
CA2456007A1 (en) 2003-02-13
CA2456007C (en) 2013-10-08
EP1428870B1 (en) 2008-11-19
PT1428870E (pt) 2009-02-16
ATE414761T1 (de) 2008-12-15
US7468190B2 (en) 2008-12-23
ES2316590T3 (es) 2009-04-16
WO2003012075A1 (es) 2003-02-13

Similar Documents

Publication Publication Date Title
ES2192949B1 (es) Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop.
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
NZ593220A (en) Immunostimulatory oligonucleotides
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
HK1145627A1 (en) Attenuated mycoplasma gallisepticum strains
HK1078902A1 (en) Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
AR029622A1 (es) Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
ATE340853T1 (de) Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung
PL349320A1 (en) Genes and proteins, and their use
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
HUP0401077A2 (hu) Mycoplasma bovis fertőzési modell, valamint eljárások M. bovis bejuttatására és tüdőgyulladásos tüdőléziók indukálására
GB0307089D0 (en) Live vaccine strain
ATE442857T1 (de) Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
HUP9702355A2 (hu) Avirulens Mycoplasma synoviae, és az ezt tartalmazó vakcina
RU2339692C2 (ru) Туберкулезные вакцины, содержащие рекомбинантные штаммы бцж, экспрессирующие аланиндегидрогеназу, сериндегидратазу и/или глютаминсинтетазу
RU2002122063A (ru) Штам бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины
Young Novel strategies for intervention targeted at mycobacterial persistence
DE69833183D1 (de) Impfstoff gegen renibacterium salmoninarum
Tian et al. live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model
Raoult et al. subsp. Bartonella vinsonii
Low A mouthful of bacterial diversity
MXPA03010910A (es) Metodo para generar microorganismos no virulentos a partir de patogenicos, mediante modificacion genetica permanente de su membrana bioligica, para producir vacunas.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031016

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192949B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211112